- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Articles from ACR Convergence 2020
Here are the top 5 biosimilar articles from the American College of Rheumatology (ACR) Convergence 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
The American College of Rheumatology’s (ACR) Convergence 2020 was the annual meeting of the ACR. This year, due to the pandemic, the meeting was hosted virtually from November 5 to 9. During the conference, a number of study findings were presented on biosimilars used to treat rheumatic diseases. Here are the top 5 biosimilar articles from ACR Convergence 2020.
Number 5: One study of multiple biosimilar switches for patients with a variety of rheumatic musculoskeletal diseases demonstrated a high rate of patient retention and no major changes in disease activity or function.
Number 4: In a study of the use of infliximab biosimilars among patients with gastrointestinal and rheumatologic conditions, investigators found high adherence.
Number 3: Investigators presented evidence of what they say are successful, first-time tests of a multibiomarker disease activity score in patients with rheumatoid arthritis.
Number 2: Separate studies, including one on application methods for Celltrion’s adalimumab biosimilar candidate (CT-P17), were reported at the ACR Convergence 2020.
Number 1: Poster presentations at the meeting shed light on performance of Pfizer’s and Celltrion’s versions of adalimumab biosimilars.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Equivalence Confirmed: CT-P41 Paves the Way for Affordable Osteoporosis Care
January 8th 2025Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis, paving the way for improved accessibility and cost savings in osteoporosis treatment.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Study Confirms CT-P42 Therapeutic Equivalence to Reference Aflibercept in DME
January 6th 2025The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving visual acuity in patients with diabetic macular edema (DME), with comparable efficacy, safety, pharmacokinetics, and immunogenicity at 24 weeks, with more long-term data expected.
